skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Introduction

Around 330,000 patients with mild cognitive impairment or mild to moderate Alzheimer’s disease will receive immunotherapies annually by 2021, allowing the treatment of this disease to reach an entirely new audience. This is just one catalyst contributing to the market value doubling in size over 2012-21. Datamonitor Healthcare has used a patient based approach to size the commercial potential of Alzheimer’s disease across the US, Japan and five major EU market. 

How will our Alzheimer’s disease forecast report benefit you?

  • Gain competitive insight
    Access an in-depth patient based report that details individual drugs in each disease setting via sales values and patient value, allowing you to assess your product positioning against those with the highest commercial value.
  • Prepare for market change
    Understand how the growing treated population within the Alzheimer’s market will change due to a shift in the diagnosing timeline over the forecast period to establish where you should be targeting new product developments.
  • Benchmark your product
    Understand how two new emerging product classes, 5-HT6 receptor antagonists and alpha-7 nAChR agonists, will compete against and complement existing market products, to help benchmark your product against new emerging classes and identify where your product will fit within the new market.
  • Identify investment opportunities
    See how potential disease modifying therapies, such as solanezumab the one pipeline drug suited to treat early stage patients, perform in various stages of Alzheimer’s disease, to help you identify any unmet needs within the early stages of the disease.

Key questions answered

  • How does the value of treating each stage of Alzheimer’s disease progress over the next decade and which factors are contributing to this?
  • How will Pfizer/Eisai’s Aricept, formerly the highest selling brand in the market, perform with the emergence of generic competition?
  • Which developmental products will emerge from the pipeline and what are their commercial potentials?
  • How does the Alzheimer’s disease market differ in each major region and which events will influence their future direction?

Read also

  • Biomedtracker: see the drug development process through anal...

    Key Potential Drug Launches in 2022

    Released July 22, 2021. Contains information like likelihood of approval (LOA) ratings and upcoming catalysts that are current as of April 2021.

  • Biomedtracker: see the drug development process through anal...

    2020 Deal-Making Roundup

    Against a backdrop of unprecedented disruption, the biopharma and medtech industries reached incredible heights for deal-making activity during 2020.

    Topics Drug Review Coronavirus

  • Datamonitor Healthcare: data analysis and insight, Biomedtra...

    2021 Post-ASCO Insights and Analysis

    The American Society of Clinical Oncology (ASCO) hosted its annual meeting from June 4-8 2021 and our team has the exclusive insights and analysis you can access today.

    Topics Cancer

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: